Revenue segments as reported by the company.

Proprietary Products

Contract - Manufactured Products

Eliminations

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Research and development

Selling, general and administrative

Other (income) expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

West Pharmaceutical Services

West Pharmaceutical Services, Inc. manufactures and markets pharmaceuticals, biologics, vaccines and consumer healthcare products. It operates through the following business segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment and drug delivery products, along with analytical lab services, to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. The company was founded by Herman O. West on July 27, 1923 and is headquartered in Exton, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

West Pharmaceutical Services reports solid growth and strategic investments

West Pharmaceutical Services showed resilience with 8% organic sales growth in 2022 despite challenges.
2023 guidance includes growth projections, margin expansion, and a share repurchase program.
The company's pricing strategy and investments in high-value products position it for future success.
Despite COVID impacts, West remains focused on growth opportunities and sustainability efforts.

West Pharmaceutical Services reports solid Q1 performance and growth outlook

West Pharmaceutical Services (WST) showcased strong Q1 performance with growth in key market units and ongoing investments in capacity expansion.
Despite challenges such as declining profitability metrics and inflationary pressures, the company remains optimistic about its full-year outlook and growth prospects.
Opportunities lie in sustained growth in Contract Manufacturing, revenue diversification, and a focus on margin expansion to drive future financial success.
Analysts' inquiries highlighted areas for improvement, signaling a proactive approach to addressing challenges and capitalizing on growth opportunities.

West Pharmaceutical Services excels in Q2, eyes growth opportunities

West Pharmaceutical Services reported strong Q2 performance driven by key business units and growth drivers, with a focus on sustainability and capacity investments. Despite challenges like margin expectations and external events, the company remains well-positioned for growth. Opportunities lie in revenue pickup in Q4, strategic partnerships, and global market expansion.

West Pharmaceutical Services reports solid Q3 performance and eyes growth through automation and strategic investments

West Pharmaceutical Services delivered solid Q3 performance with growth in net sales and adjusted EPS, despite challenges in inventory management and capacity constraints.
The company's strategic investments in automation and capacity expansions position it well for future growth opportunities in HVP and biologics.
While facing industry challenges and uncertainties, West remains confident in meeting or exceeding its growth targets for 2024 through continuous monitoring and adjustment.
Maintaining a strong focus on customer commitments and market differentiation, West Pharmaceutical Services aims to drive growth through innovation and operational efficiency.

West Pharmaceutical Services reports solid Q4 results amidst 2024 challenges

West Pharmaceutical Services navigated challenges in Q4 2023 with solid performance and a focus on growth drivers for 2025, despite anticipated hurdles in 2024.
The company's strategic approach to capital allocation, market share strength, and product focus position it well for future growth and resilience.
Balancing challenges with opportunities, West Pharmaceutical Services aims to sustain growth momentum, overcome obstacles, and drive efficiency and innovation.
With a strong order book outlook, normalized margin rates, and a focus on market trends, West Pharmaceutical Services is poised for continued success and market leadership.

West Pharmaceutical Services navigates mixed Q1 performance with strategic resilience

West Pharmaceutical Services faced challenges in Q1 2024 but demonstrated strengths in strategic planning and resilience.
The company's focus on capacity expansions and maintaining guidance reflects a commitment to long-term growth.
Addressing challenges related to customer destocking and financial performance will be crucial for seizing opportunities and enhancing competitiveness.

West Pharmaceutical Services faces Q2 challenges but eyes future growth

West Pharmaceutical Services navigated challenges in Q2 2024 due to customer destocking, impacting organic sales and gross profit margin. Despite this, management remains optimistic about future growth prospects, aiming to return to a 7% to 9% growth construct. Adjusted full-year guidance reflects a more gradual recovery, with a focus on strategic investments for future growth.

West Pharmaceutical Services reports solid Q3 results amid margin challenges

West Pharmaceutical Services reported solid Q3 performance but faced declines in key financial metrics compared to the previous year. The company is focusing on leveraging its strengths in biologics and expertise to drive future growth, while addressing challenges in margins and organic sales. Opportunities lie in improving performance in Q4 and capitalizing on increased guidance for net sales and adjusted EPS.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

- Conference Call Scheduled for 9 a.m. EDT Today - EXTON, Pa.

West Announces First-Quarter 2022 Results and Declares Third-Quarter 2022 Dividend

West Pharmaceutical Services is becoming a vital component of the healthcare industry. West has provided critical products and services required for COVID-19 vaccines. WST is a "Dividend Aristocrat" and has raised its dividend for 29 consecutive years. However, WST's dividend yield is a trivial 0.21% with a payout ratio of 8.01%.

Healthy Dividends: Organic Growth Points North For West Pharmaceutical Services

West Pharmaceutical's (WST) first-quarter results are likely to reflect strength in the Proprietary Products business.

What's in Store for West Pharmaceutical's (WST) Q1 Earnings?

EXTON, Pa. , April 14, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release first-quarter 2022 financial results before the market opens on Thursday, April 28, 2022, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.

West to Host First-Quarter 2022 Conference Call

PORTSMOUTH, N.H. , April 7, 2022 /PRNewswire/ -- Medical technology company, Pneuma Systems Corporation, has entered a multi-faceted business collaboration with West Pharmaceutical Services, Inc. (NYSE: WST) with the goal of improving the patient's experience with drug therapy.

Pneuma Systems collaborates with West Pharmaceutical Services, Inc. to improve the patient experience

EXTON, Pa. , April 4, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that its Scientific Insights Lab team members, Liang Fang and Marissa Rase, received the 2021 Fred Simon Award, and its Chief Scientific Officer, Fran DeGrazio, received the 2021 Edward Smith Packaging Science Award at the 2022 PDA Annual Meeting in Dallas. The Frederick D.

West Receives Fred Simon Award and Edward Smith Packaging Science Award at 2022 PDA Annual Meeting

West to moderate sessions, give keynote presentation, and share scientific posters, highlighting expertise in ensuring quality, sterility and stability of injectable drug products EXTON, Pa. , March 31, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced its participation at the 2022 PDA Annual meeting to include sharing the latest in packaging science with scientific talks, moderating session panels and presenting posters, throughout the meeting.

West to Showcase Leadership and Advancements of Packaging Science at the 2022 PDA Annual Meeting

Cardinal Health

McKesson

Despite the COVID-19 pandemic-induced challenges, teledentistry coupled with AI & Robotics should lend support to the Zacks Medical - Dental Supplies industry. MCK, WST and CAH are well-poised to gain from the prospects.

3 Lucrative Stocks From the Promising Dental Supplies Industry

Anthem

Centene

Quest Diagnostics

Danaher

PerkinElmer

UnitedHealth Group

When the markets go through the massive transitions they're seeing right now, it's a great time to add quality healthcare stocks. The post 7 Healthcare Stocks to Buy for the Long Term appeared first on InvestorPlace.

7 Healthcare Stocks to Buy for the Long Term

EXTON, Pa., Feb. 28, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced Eric M. Green, President and CEO, will assume the additional responsibility of Chair of the Company's Board of Directors, effective as of West's next Annual Shareholders' Meeting, which is expected to be May 24, 2022.

West Names President and CEO Eric M. Green as Chair of the Board

EXTON, Pa., Feb. 23, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that the Company's Board of Directors has approved a second-quarter 2022 dividend of $0.18 per share. The dividend will be paid on May 4, 2022, to shareholders of record as of April 20, 2022.

West Announces Second-Quarter 2022 Dividend

West Pharmaceutical Services, Inc. (WST) CEO Eric Green on Q4 2021 Results - Earnings Call Transcript

West Pharmaceutical's (WST) fourth-quarter earnings reflect strength in the Proprietary Products segment and margin expansion.

West Pharmaceutical (WST) Q4 Earnings & Revenues Top Estimates

West Pharmaceutical (WST) delivered earnings and revenue surprises of 6.25% and 3.06%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

West Pharmaceutical Services (WST) Surpasses Q4 Earnings and Revenue Estimates

EXTON, Pa., Feb. 17, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST) today announced its financial results for the fourth-quarter and full-year 2021 and introduced full-year 2022 financial guidance. Fourth-Quarter and Full-Year 2021 Summary (comparisons to prior-year period) Fourth-quarter 2021 net sales of $730.8 million grew 26.0%; organic sales growth was 28.3%.

West Announces Fourth-Quarter and Full-Year 2021 Results

West Pharmaceutical's (WST) fourth-quarter results are likely to reflect strength in the Proprietary Products business.

What's in Store for West Pharmaceutical's (WST) Q4 Earnings?

In the latest trading session, West Pharmaceutical Services (WST) closed at $400.69, marking a -0.01% move from the previous day.

West Pharmaceutical Services (WST) Stock Sinks As Market Gains: What You Should Know

EXTON, Pa., Feb. 3, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that it will release fourth-quarter and full-year 2021 financial results before the market opens on Thursday, February 17, 2022, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.

West to Host Fourth-Quarter and Full-Year 2021 Conference Call

In the latest trading session, West Pharmaceutical Services (WST) closed at $393.22, marking a +0.05% move from the previous day.

West Pharmaceutical Services (WST) Gains But Lags Market: What You Should Know

Corning

EXTON, Pa., Jan. 25, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced an exclusive supply and technology agreement with Corning Incorporated (NYSE: GLW). The new collaboration includes a multimillion-dollar investment to expand Corning's Valor® Glass technology to enable advanced injectable drug packaging and delivery systems for the pharmaceutical industry with the goal of advancing patient safety and expanding access to life-saving treatments.

West Announces Landmark Collaboration with Corning in Pharmaceutical Injectable Drug Delivery

Amphenol

Activision Blizzard

Ball

JPMorgan Chase & Co

Lowe's

Mastercard

MSCI

NVIDIA

Starbucks

Charles Schwab

SS&C Technologies Hlds

Skyworks Solutions

Texas Instruments

Visa

I present my top 15 high-growth dividend stocks to consider during the month of January. Last month's list returned 4.65% in December to finish out 2021 with a total return of 33.52%.

My Top 15 High Growth Dividend Stocks For January 2022

EXTON, Pa., Jan. 5, 2022 /PRNewswire/ -- West Pharmaceutical Services, Inc. (NYSE: WST), a global leader in innovative solutions for injectable drug administration, today announced that the Company's Board of Directors have approved a first-quarter 2022 dividend of $0.18 per share.  The dividend will be paid on February 2, 2022, to shareholders of record as of January 19, 2022.

West Announces First-Quarter 2022 Dividend and 2022 Share Repurchase Program

Accenture Plc

Applied Materials

Bank of New York Mellon

Blackrock Inc

Comcast

Costco

Ecolab

Expeditors International of Washington

General Dynamics

Home Depot

Hershey

Lockheed Martin

McCormick

Northrop Grumman

Roper Technologies

T. Rowe Price Group

U.S. Bancorp

Vanguard Dividend Appreciation ETF

There are 23 stocks on my dividend growth watchlist for January 2022. Six of the stocks on my watchlist are currently undervalued based on dividend yield theory.

Dividend Growth Stock Watchlist - January 2022

West Pharmaceutical Services (WST) closed at $459.84 in the latest trading session, marking a +1.37% move from the prior day.

West Pharmaceutical Services (WST) Outpaces Stock Market Gains: What You Should Know

West Pharmaceutical (WST) possesses solid growth attributes, which could help it handily outperform the market.

News for West Pharmaceutical Services Stock (WST)